The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Official Title: A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy
Study ID: NCT00878722
Brief Summary: An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not suitable for standard intensive therapy.
Detailed Description: This trial is an open-label, multi-centre, dose-escalation Phase I/II study to evaluate safety, explore efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with idarubicin administered in two different schedules in patients with AML. The PXD101 plus idarubicin treatment will be repeated at suitable intervals (target is every 3 weeks for schedule A and every 2 weeks for schedule B) depending upon toxicities or disease progression. Safety and efficacy assessments will be performed at every cycle. Schedule A uses PXD101 by 30 min infusion daily for 5 days every 3 weeks with escalating doses of idarubicin. Schedule B uses escalating doses of continuous infusion (48h) of PXD101 alone or in combination with idarubicin. In both regimens the trial may be expanded at the Maximum Tolerated Dose (MTD).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU Lapeyronie, Montpellier, , France
Hôpital St. Louis, Paris, , France
Uniklinik Homburg, Homburg, , Germany
Uni Hospital Marburg, Marburg, , Germany
Universitätsklinikum Ulm, Ulm, , Germany
Christie Hospital NHS Trust, Manchester, , United Kingdom
Name: e-mail contact via enquiries@topotarget.com
Affiliation: Valerio Therapeutics
Role: STUDY_CHAIR